Drug Trial Radar · NCT07720375
A Study of 24 to 52 Weeks Treatment to Evaluate The Efficacy And Safety of Galvokimig in Adult Study Participants With Non-Cystic Fibrosis Bronchiectasis
Last checked: Nov 19, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
300
Planned (sponsor's estimate)
Start
Aug 5, 2026
Primary completion
Feb 28, 2029
Study completion Apr 26, 2029
Sponsor
- Lead sponsor
- UCB Biopharma SRLUCB
- Sponsor type
- Industry
- First posted
- Jul 22, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study is to investigate the efficacy of galvokimig versus placebo on the time to the first pulmonary exacerbation in study participants with non-cystic fibrosis bronchiectasis (NCFB)
Conditions
- Non-cystic Fibrosis Bronchiectasis
Interventions
GalvokimigBiological
Drug: Galvokimig Pharmaceutical form: Solution for injection
PlaceboBiological
Drug: Placebo Pharmaceutical form: Solution for injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time from intervention assignment to first moderate or severe pulmonary exacerbationTime frame: Up to Week 52
Locations
7 sites in 1 country. Site status is shown where the registry gives one.
Ncfb01 50012
Newport Beach, California · Recruiting
Ncfb01 50003
Brandon, Florida · Recruiting
Ncfb01 50005
Plantation, Florida · Recruiting
Ncfb01 50004
DuBois, Pennsylvania · Recruiting
Ncfb01 50007
Rock Hill, South Carolina · Recruiting
Ncfb01 50001
McKinney, Texas · Recruiting
Ncfb01 50010
Mesquite, Texas · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.